NCT01835548 - NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG

NT0102

NT0102 (methylphenidate polistirex \[MPP\] extended release \[XR\] ODT) was given once daily at a dose equivalent to 20-60 mg methylphenidate hydrochloride.

DRUG

Placebo

Matching ODT placebo was given once daily.

Trial Locations (4)

27705

Duke University, Durham

32751

Florida Clinical Research Center, Maitland

34208

Florida Clinical Research Center, Bradenton

89128

Center for Psychiatry and Behavioral Medicine, Las Vegas